Compare Abeona Therapeutics Inc (ABEO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Stanley Black & Decker, Inc. trades at $86.27 (market cap $13.89B). The key difference: Stanley Black & Decker, Inc. is far larger — about 37.2× Abeona Therapeutics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.71% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SWK | |
|---|---|---|
Market Cap | $373.32M | $13.89B |
Sector | Health | — |
52-Week High | $7.23 | $94.12 |
52-Week Low | $4.17 | $62.12 |
Enterprise Value | $228.22M | $20.06B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Stanley Black & Decker (SWK) trades at $89.37, down 2.75% today, with a bullish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stabilization around $15B annually, while net income improved to $401.9M in 2025. Debt reduction remains a priority, supported by positive operating cash flow of $971.2M.
SWK offers a turnaround story with improving profitability and shareholder returns via dividends, but faces headwinds from weak Tools & Outdoor demand and high debt levels. Analyst consensus is mixed with a $82.75 price target below current levels, suggesting cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
